Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD

Summary

This clinical trial evaluates the long-term safety and efficacy of 0.75 mg HSK39004 Dry Powder Inhaler administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive pulmonary disease (COPD), including both newly enrolled and those who have completed prior participation in the HSK39004-201, HSK39004-T1-201, or HSK39004-T1-202 studies as a long-term extension.

Timeline

Start

2026-03

Primary completion

2027-07

Completion

2027-08

Drugs

Indications